|Share this content:|
|Home||About Us||Our Attorneys||Cases||Practice Areas||Settlement Notices||News & Events||Contact Us|
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Dynavax Technologies Corporation To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Dynavax Technologies Corporation (“Dynavax” or the “Company”) (NASDAQ: DVAX).
The investigation focuses on whether Dynavax made materially false and misleading statements regarding the viability of HEPLISAV, the Company’s lead product candidate. Specifically, the investigation focuses on whether Dynavax failed to disclose: (i) that the clinical trial for HEPLISAV was flawed in that it was not representative of the United States population and did not provide information regarding concurrent use of HEPLISAV with other vaccines; and (ii) the Company did not provide the Food and Drug Administration (“FDA”) with adequate information regarding HEPLISAV manufacturing processes and controls.
On June 10, 2013, Dynavax issued a press release announcing that the FDA would require additional safety trials prior to granting approval of HEPLISAV. Following this news, Dynavax’s stock price dropped $1.07 or 43%.
If you invested in Dynavax stock or options between April 26, 2012 and June 10, 2013 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com or firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Dynavax’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you. If you want to be a Lead Plaintiff or join
this action now, please click HERE.
*The submission of this form does not create an attorney-client relationship.